Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

SUSPENDED

NCT03952598

PHASE2

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

Sponsor: National Cancer Institute (NCI)

View on ClinicalTrials.gov

Summary

Background: Glioma is a type of brain cancer. Some of these tumors have gene mutations. These mutations can cause a substance called 2-HG to build up in the brain. This makes the tumors more aggressive. Researchers want to better understand 2-HG buildup in the brain. They hope this can help them design better ways to test for gliomas. Objective: To monitor the level of 2-HG in the brains of people with gliomas that have mutations in the IDH1 or IDH2 genes. Eligibility: People ages 18 and older with gliomas with mutations in the IDH1 or IDH2 genes Design: Participants will be screened with: Medical and cancer history Physical exam Reviews of their symptoms and ability to perform normal activities Blood and urine tests MRI scan Samples of their tumor from a past surgery Documentation of their diagnosis and mutation status Participants will have an initial evaluation. This will include repeats of screening tests. It will also include: Neurological exam MRS and MRI scans of the brain: Participants will lie on a table that slides into a metal cylinder. A coil or soft padding will be placed around their head. They will have a contrast agent injected into a vein. Pictures will be taken of the brain. Participants will have follow-up visits every 2-6 month for the rest of their life. Visits will include scans.

Official title: Studying the Biology of Higher-Grade Transformation in IDH-mutant Gliomas Via Longitudinal Observation of Tumor Metabolic Reprogramming Using Non-invasive Metabolic Imaging

Key Details

Gender

All

Age Range

18 Years - 120 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2019-10-16

Completion Date

2027-12-31

Last Updated

2026-06-16

Healthy Volunteers

Conditions

Glioma Gliomas High Grade Glioma Malignant Glioma Low Grade Glioma

Interventions

DRUG

HP 13C Pyruvate

Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)

DEVICE

3T MRI scanner

Research proton MRS (1H-MRS) followed by DW-MRI

* INCLUSION CRITERIA: * Participants must have histologically confirmed diffuse glioma with documented IDH1 or IDH2 mutation, confirmed by DNA sequencing the exception will be participants with brain lesions that are not safe for biopsy but clinically suspected to be diffuse glioma are allowed to enroll to the study to receive imaging study as part of the exploratory study * Participants must have measurable disease. * Age \>=18 years. Tumor biology of IDH-mutant gliomas are different in pediatric tumors. Therefore, children will be excluded from the study. * Karnofsky performance \>= 70%. * Participants must have documented normal kidney function as defined below: Creatinine within normal institutional limits OR Creatinine clearance \>60 mL/min/1.73 m2 for Participants with creatinine levels above institutional normal (Measured or calculated creatinine clearance -Participants must have adequate liver function as defined below: total bilirubin \<=2x ULN (ULN 1.3 mg/dl) except for participants with Gilbert Syndrome AST \< 3x ULN (ULN 34U/L) ALT \< 3x ULN (ULN 55U/L) -Ability of participants to understand and the willingness to sign a written informed consent document indicating that they are aware of the investigational nature of this study, and that this is not a therapeutic clinical trial. EXCLUSION CRITERIA: * Participants who have contraindication to MRI examination, including, but not limited to, unable to receive gadolinium, medical instability, or any contraindication on MR Screening Form. Pregnant individuals are excluded because MRI contrast, planned to be used on this study, may be dangerous for the fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to using of MRI contrast, breastfeeding should be discontinued for 72 hours following study imaging. * Participants weighing \> 350 lbs. (weight limit for scanner table), or unable to fit within the imaging gantry * Poorly controlled hypertension, with blood pressure \>150/90 mmHg. * Congestive heart failure with New York Heart Association (NYHA) status \> 2. * A medical history of clinically significant EKG abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) less than 1 year ago with ensuing unstable EKG. * Ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma with an exacerbation within the past year.

Locations (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States